The Biotechnology Accelerator Division identifies companies developing novel anti-cancer therapies, supportive care or diagnostics and co-funds specific projects that will enable a company to partner or raise additional funding to complete the testing, registration and marketing of new therapies or diagnostics for blood cancer indications.

TAP funding is different from the traditional grant at LLS. The TAP review process is separate from the grant process and each approved project is closely monitored by TAP staff.

For information on how to apply to TAP, please click here.

Clinical Studies Ongoing​

 

Kiadis Pharma
A Phase III, Multicenter, Randomized Controlled Study to Compare Safety and Efficacy of a Haploidentical HSCT and Adjunctive Treatment With ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted ex Vivo of Host Alloreactive T-cells, Versus a Haploidentical HSCT With Post-transplant Cyclophosphamide in Patients With a Hematologic Malignancy

The primary objective of this study is to compare safety and efficacy of a haploidentical T-cell depleted HSCT and adjunctive treatment with ATIR101 versus a haploidentical T cell replete HSCT with post-transplant administration of high dose cyclophosphamide (PTCy) in patients with a hematologic malignancy. An additional objective of the study is to compare the effect of the two treatments on quality of life.

ClinicalTrials.gov identifier: NCT02999854

​For more information contact:
Andrew Sandler, MD
+31 20 2405250
clinicaltrials@kiadis.com

For more information contact the recruiting sites:
Principal Investigator: Denis Claude Roy, MD
​Maisonneuve-Rosemont Hospital (Montreal, Canada)

Principal Investigator: Stephan Mielke, MD
​Karolinska University Hospital (Stockholm, Sweden)     

Visit the Kiadis Pharma website for additional information.​

 

miRagen
SOLAR: A Phase 2, Randomized, Open-label, Parallel-group, Active Comparator, Multi-center Study to Investigate the Efficacy and Safety of Cobomarsen (MRG-106) in Subjects With Cutaneous T-Cell Lymphoma (CTCL), Mycosis Fungoides (MF) Subtype

The main objective of this clinical trial is to study the efficacy and safety of cobomarsen (also known as MRG-106) for the treatment of cutaneous T-cell lymphoma (CTCL), mycosis fungoides (MF) subtype. Cobomarsen is designed to inhibit the activity of a molecule called miR-155 that may be important to the growth and survival of MF cancer cells. The study will compare the effects of cobomarsen to vorinostat, a drug that has been approved for the treatment of CTCL in the United States, Canada, and Australia.

Participants will be randomly assigned to receive either weekly doses of cobomarsen or daily doses of vorinostat. Participants will continue on their assigned treatment as long as their disease does not get worse or as long as they do not have unacceptable side effects. The effects of treatment will be measured based on changes in skin lesion severity, disease-associated symptoms, and quality of life, as well as the length of time that the subject's disease remains stable or improved, without evidence of disease progression. The safety and tolerability of cobomarsen will be assessed based on the frequency and severity of observed side effects. Participants assigned to receive vorinostat who experience progression of their disease during their participation in this study may have the option to be treated with cobomarsen in a separate clinical trial, if they meet the entry criteria for that study.

ClinicalTrials.gov identifier: NCT03713320

For more information contact the recruiting sites:

City of Hope 
Duarte, California, United States, 91010
Contact: Rosemarie Abary    626-218-8087    
rabary@coh.org   
Principal Investigator: Christiane Querfeld, MD   
     
Chao Family Comprehensive Cancer Center at University of California, Irvine 
Orange, California, United States, 92868
Contact: Blake Johnson    714-456-3476    
Blakej@uci.edu   
Principal Investigator: Lauren Pinter-Brown, MD         

Washington University School of Medicine 
Saint Louis, Missouri, United States, 63108
Contact: Mary Tabacchi, CCRC    314-362-8171    
mtabacch@wustl.edu   
Principal Investigator: Amy Musiek, MD     

Visit the miRagen website for additional information.

 

Forty Seven
A Phase 1b/2 Trial of Hu5F9-G4 in Combination With Rituximab in Patients With Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

This Phase 1b/2 trial will evaluate Hu5F9-G4 in combination with rituximab. Hu5F9-G4 is a monoclonal antibody which is designed to block a protein called CD47, which is widely expressed on human cancer cells. Blocking CD47 with Hu5F9-G4 may enable the body's immune system to find and destroy the cancer cells. Rituximab is a monoclonal antibody drug that is used for treatment of non-Hodgkin's lymphoma and other types of cancer.

The major aims of the trial are: (Phase 1b) to investigate the safety and tolerability of sequential dose cohorts and to determine a recommended Phase 2 dose for Hu5F9-G4 in combination with rituximab, and (Phase 2) to evaluate the efficacy of Hu5F9-G4 in combination with rituximab in patients with indolent lymphoma or diffuse large B-cell lymphoma as measured by the overall response rate.

ClinicalTrials.gov identifier: NCT02953509

For more information contact:
Mark Chao, MD PhD
650-352-4150
medical@fortyseveninc.com

For more information contact the recruiting sites:

University of Alabama At Birmingham (UAB) Comprehensive Cancer Center
Birmingham, Alabama, United States, 35294
Contact: Hope Line Patient Referral    205-996-4673    
phase1referral@uab.edu   
Principal Investigator: Andres Forero, MD         

City of Hope 
Duarte, California, United States, 91010
Contact: Imran Qasim    626-218-9108    
iqasim@coh.org   
Principal Investigator: Leslie Popplewell         

Stanford University 
Palo Alto, California, United States, 94304
Contact: Sipra Choudhury, M.Sc,CCRP    650-736-2563    
schoudhury@stanford.edu   
Contact: Thu Tran    650-723-0530    
Ttran49@stanford.edu   
Principal Investigator: Ranjana Advani, MD         

University of Chicago 
Chicago, Illinois, United States, 60637
Contact: Jennifer Madden    773-834-4574    
jmadden@medicine.bsd.uchicago.edu   
Principal Investigator: Sonali Smith, MD         

NIH 
Bethesda, Maryland, United States, 20892
Contact: Maureen Edgerly, RN    240-760-6013    
NCIMO_Referrals@mail.nih.gov   
Principal Investigator: Mark Roschewski, MD         

Dana Farber Cancer Institute 
Boston, Massachusetts, United States, 02215
Contact: Grace Fairchild    617-632-6840    
Grace_Fairchild@DFCI.HARVARD.edu   
Principal Investigator: Ann LaCasce, MD         

Washington University School of Medicine 
Saint Louis, Missouri, United States, 63110
Contact: Nancy Borror    314-362-3257    
nborror@wustl.edu   
Principal Investigator: Nancy Bartlett, MD         

Carolinas Healthcare Systems- Levine Cancer Institute 
Charlotte, North Carolina, United States, 28024
Contact: Angela Anderson    980-442-2365    
angela.p.anderson@carolinashealthcare.org   
Principal Investigator: Nilanjan Ghosh, MD         

Sarah Cannon Research Institute 
Nashville, Tennessee, United States, 37203
Contact: Ian Flinn, MD         
Contact    615-339-4214    
asksarah@sarahcannon.com   
Principal Investigator: Ian Flinn, MD         

Oxford University Hospital 
Oxford, Oxforshire, United Kingdom, OX3 7LE
Principal Investigator: Graham Collins, MB   

Visit the Forty Seven website for additional information.

 

Affimed
​GHSG-AFM13 An Open-label, Multicenter Phase II Trial With AFM13 in Patients With Relapsed or Refractory Hodgkin Lymphoma

The study is designed:

• to demonstrate efficacy of AFM13 with an optimized treatment schedule

• to decide whether AFM13 warrants further investigation in a phase III clinical trial

ClinicalTrials.gov identifier: NCT02321592

For more information contact:
Michael Fuchs
Department of Medicine, Cologne University Hospital
Cologne, Germany
ghsg@uk-koeln.de
Principal Investigator: Andreas Engert, MD  

A Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination With Pembrolizumab in Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (KEYNOTE- 206)

The purpose of this study is to establish a dosing regimen for the combination therapy of AFM13 and pembrolizumab (MK-3475) in patients with relapsed or refractory (R/R) Hodgkin Lymphoma (HL) and to assess the safety and tolerability of this combination therapy.

ClinicalTrials.gov identifier: NCT02665650 (ACTIVE, BUT NOT RECRUITING)

Visit the Affimed website for additional information.​

 

Verastem, Inc.
A Phase I Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

The phase I portion of the study is designed to determine the MTD of duvelisib with romidepsin and duvelisib with bortezomib. All patients must have a relapsed or refractory T-cell lymphoma. The design is a standard 3+3 dose escalation of two parallel phase I studies. Patients will be enrolled in Arms A (Romidepsin + duvelisib) and B (Bortezomib + duvelisib) of the study starting at dose level 1.

Three to six patients will be initially treated in each dose level until the MTD is determined. If dose level 3 is achieved without exceeding one dose limiting toxicity (DLT) after 1 cycle that dose level will be deemed the "optimal dose" and the study will proceed to the cohort expansion phase. Should patients be found to develop significant toxicity or not tolerate therapy at the MTD with repeated cycles of therapy, the "optimal dose" may be determined to be at dose levels less than the MTD. Patients with measurable disease treated in the phase I at the optimal dose will be counted towards the accrual of the expansion cohorts by disease subtype and all efficacy and toxicity endpoints.

Cohort Expansion Phase: The expansion cohorts will further assess toxicity and safety and allow a preliminary assessment of the efficacy of the combination to provide background for a potential future subtype specific phase II study. The assessment of efficacy will be descriptive.

ClinicalTrials.gov identifier: NCT02783625

For more information contact:
Contact: Steven Horwitz, MD 212-639-3045
Contact: Alison Moskowitz, MD 212-639-4839

Visit the Verastem website for additional information.

 

OncoPep
A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM (Active, not recruiting)

This research study is a Phase I clinical trial, which tests the safety of an investigational intervention and also tries to define the appropriate dose of the investigational intervention to use for further studies. "Investigational" means that the intervention is being studied.

In this research study, the investigators are studying Smoldering Multiple Myeloma. Smoldering Multiple Myeloma is an early precursor to a rare blood cancer known as Multiple Myeloma, which affects plasma cells. The study will test two different combinations of the study drugs; a combination of the vaccine (PVX-410) along with Citarinostat (CC-96241) and triple combination of the vaccine, Citarinostat, and Lenalidomide.

The vaccine (PVX-410) is a multi-peptide vaccine that contains four synthetic peptides that together are intended to induce a T cell-mediated immune response against the myeloma. The FDA (the U.S. Food and Drug Administration) has not approved PVX-410 as a treatment for any disease.

Citarinostat is an orally active, small-molecule Histone Deacetylase (HDAC) Inhibitor which is being combined here to further augment the immune activity of the vaccine. Citarinostat has not been approved by the FDA as a treatment for any disease.

Lenalidomide is commercially available analogue of thalidomide with immunomodulatory, antiangiogenic, and antineoplastic properties that has demonstrated an increase in immune activity in previous trials. The FDA has approved Lenalidomide as a treatment option for Smoldering Multiple Myeloma. Lenalidomide is being added to the combination of the vaccine and Citarinostat because it is hypothesized that co-administration of lenalidomide along with Citarinostat would further enhance the T cell-mediated immune response induced by PVX-410.

ClinicalTrials.gov identifier: NCT02886065

For more information contact the recruiting sites:
Massachusetts General Hospital 
Boston, MA 02115 
(617) 726-0711      
Principal Investigator: Noopur Raje, MD
  
Beth Israel Deaconess Medical Center 
Boston, Massachusetts, United States, 02115
Contact: David Avigan, MD      
  
Dana-Farber Cancer Institute
Boston, Massachusetts, United States, 02215
Contact: Paul Richardson, MD   

Visit the OncoPep website for additional information.

 

Sutro
​Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell Malignancies

This study is a first-in-human Phase 1, open-label, multicenter, dose escalation study with dose expansion to identify the maximum tolerated dose (MTD), the recommended phase 2 doses (RP2D) and to evaluate the safety, tolerability, and preliminary anti-tumor activity of STRO-001 in adult subjects with B-cell malignancies (MM and NHL) who are refractory to, or intolerant of, all established therapy known to provide clinical benefit for their condition (i.e., trial subjects must not be candidates for any regimens known to provide clinical benefit). The study will consist of two parts: Part 1, dose escalation, and Part 2, dose expansion.

During Part 1 (dose escalation), an accelerated dose titration design will be applied to cohorts A (MM) and B (NHL). Doses will be escalated using an N-of-1 until the first instance of a treatment-related, clinically relevant Grade 2 non-hematologic toxicity or a Grade 3 hematologic toxicity of any type is observed during Cycle 1 (first 28 days). Any event meeting these criteria will be reviewed and confirmed by the Safety Evaluation Team (SET). Each dose escalation cohort will be assessed independently. When these criteria are met then the dose is expanded with 2 additional subjects and the standard 3+3 trial design is used for all further dosing cohorts. The dose escalation (Part 1) phase of the study will be complete when the MTD is determined and the recommended dose for Part 2 (dose expansion) is identified. The RP2D will be selected based on the safety, tolerability and exposure of STRO-001, and will be the end of Part 1 of the study. After determination of the RP2D, subjects with MM or NHL will be enrolled into indication specific dose expansion cohorts (Part 2). The accelerated dose titration (N-of-1) design with seamless transformation into a traditional 3+3 design allows for very low starting doses to be evaluated in fewer patients.

ClinicalTrials.gov identifier: NCT03424603

For more information contact Sutro or the recruiting sites:

Shannon Matheny, PhD
1-650-676-4610
STRO-001ClinDev@sutrobio.com

City of Hope Medical Center
Duarte, California, United States, 91010
Contact: Amrita Krishnan, M.D.   
626-256-4673    
akrishnan@coh.org   

University of California San Francisco HDF Comprehensive Cancer Center
San Francisco, California, United States, 94143
Contact: Danielle Kilayko    415-502-3549    
Danielle.Kilayko@ucsf.edu   
Principal Investigator: Nina Shah, MD    

Rocky Mountain Cancer Center 
Aurora, Colorado, United States, 80012
Contact: Mary Catherine Jerome   
281-541-9285    
MaryCatherine.Jerome@McKesson.com   
Principal Investigator: John Burke, MD         

Emory University Winship Cancer Institute 
Atlanta, Georgia, United States, 30322
Contact: John Bourgeois    404-778-1802 ext 30577    
John.bourgeois@emoryhealthcare.org   
Principal Investigator: Jonathan Kaufman, MD         

Willamette Valley Cancer Institute and Research Center 
Eugene, Oregon, United States, 97401
Contact: Jeanne Schaffer, RN    541-521-8773   
jeanne.schaffer@usoncology.com   
Principal Investigator: Jeff Sharman, MD         

Texas Oncology 
Austin, Texas, United States, 78705
Contact: Mary Catherine Jerome   
281-541-9285    
MaryCatherine.Jerome@McKesson.com   
Principal Investigator: Jason Melear, MD         

Virginia Cancer Specialists
Fairfax, Virginia, United States, 22031
Contact: Karin Choquette, MSN/RN   
571-389-0873    
Karin.Choquette@USOncology.com   
Principal Investigator: Alexander Spira, MD, PhD         

Medical College of Wisconsin 
Milwaukee, Wisconsin, United States, 53226
Contact: General Cancer Center Info   
866-680-0505 ext 8900    
cccto@mcw.edu   
Principal Investigator: Nirav Shah, MD         

Visit the Sutro website for additional information.

 

Selvita S.A.
A Phase Ib Study of SEL120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

SEL120 is an ATP-competitive and selective inhibitor of CDK8 and a closely related serine kinase, CDK19. CDK8 is a part of a multi-protein complex that regulates gene expression and is distinct from CDK4 or CDK6, which play a role in cell cycle progression. In laboratory experiments, treatment with SEL120 has been shown to result in the death of AML cells especially with elevated phosphorylation of STAT5 and stem cell characteristics, which is significant because AML stem cells are typically resistant to conventional therapies and thereby mediate relapsed disease. Moreover, the status of phosphorylation of STAT5 may provide a useful biomarker for action of the drug. The molecular mechanism of action involves modulation of various oncogenic transcriptional programs that are critical to the survival of AML cells. This unique mechanism, which does not overlap with existing therapies, may allow the development of highly effective combination therapies that may be required to provide long term control of AML in patients.

This first-in-human study will evaluate SEL120, a novel small molecule CDK8/19 inhibitor, in patients with Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (HR-MDS), in terms of selection of the recommended dose for further clinical development and assessment of safety, tolerability, preliminary anti-leukemic activity, as well as pharmacokinetic and pharmacodynamic profiles. The first part of the study consists of dose-escalation cohorts where patients will receive ascending doses of SEL120 to determine the recommended dose (RD) for further clinical development. The second part of the study is an enrichment cohort where additional 6 to 20 patients will be treated with SEL120 to support the evaluation of the RD.

ClinicalTrials.gov identifier: NCT04021368

For more information contact Selvita or the recruiting sites:

Tennessee Oncology
Nashville, Tennessee, United States, 37203
Contact: William Donnellan, MD  

Visit the Selvita website for additional information.

 

Other Active Programs

Criteria/How to Apply

When a company seeks funding, it needs to demonstrate the compounds, biologics or diagnostics in development:

• Are highly innovative

• Have therapeutic potential in blood cancer field with near-term probability of providing benefits to patients

A company also needs to demonstrate:

• Competency of its management and scientific staff

• Financial strength

• Freedom to operate, including intellectual property protection

• Well-designed regulatory and commercialization strategies

TAP builds business alliances and collaborations with companies. The funding TAP provides is not a grant, nor for building the company's infrastructure. It is designed to complement the company resources to accelerate the development of a therapeutic asset, supportive care or diagnostic.

The TAP team reviews all companies that make an inquiry but will only invite those deemed to meet diligence criteria to complete a proposal template and be considered for TAP funding.

To submit an inquiry for initial non-confidential review, please click here to download the form.

Send a completed inquiry form and non-confidential presentation to Dr. Jun Xu, Executive Director, Therapy Acceleration Program®, The Leukemia & Lymphoma Society, 3 International Drive, Suite 200, Rye Brook, NY 10573; jun.xu@lls.org.